One-month results of the Low-Risk Bicuspid study suggest Medtronic’s Evolut self-expanding transcatheter aortic valve replacement (TAVR) system may be an appropriate alternative to surgery in low-risk patients with a bicuspid aortic valve, a valve with only two leaflets.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?